The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a ...

Vascular dementia is the second-most common form of dementia after Alzheimer's. About 2.7 million people in the U.S. are thought to have mixed dementia or vascular dementia, which is caused by strokes ...

The drugmaker says an oral version of Wegovy improved Alzheimer’s-related biomarkers, but didn’t delay the disease’s ...

An older oral version of the company's semaglutide drug failed to meet its main goal in late-stage trials testing whether the ...

As competitive as the obesity drug market has become, Novo Nordisk's decision to slash the prices of its GLP-1 agonist drugs ...

New GLP-1 weight-loss drugs may preserve muscle, protect skin, and reduce the risk of "Ozempic face." Experts explain what ...

Eli Lilly, the maker of hugely popular weight loss drugs, has reached $1 trillion in value, becoming the first publicly ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Orforglipron is Lilly’s oral GLP-1 in phase 3 development as a treatment for diabetes and obesity. The FDA is expected to approve the drug in March 2026. Lilly’s November news release states that the ...

Vanda advances with strong Fanapt growth, late-stage catalysts, GLP-1 potential, higher investment and solid balance sheet ...